ABBV-2B04

N/A

Report date: 2024/07/03 21:31:43

Base Information

Drug NameABBV-2B04
Drug Alias NameABBV-2B04
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionVirus internalization inhibitorsAnti-Coronavirus spike glycoprotein
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto RicoNetherlands +[5] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesWashington UniversityAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A